C12Y 304/22061
Caspase-8
Official title: Caspase-8 (3.4.22.61)
C12Y304/22061 (Caspase-8) appears on 8 US grants and 25 published applications in this corpus.
Search patents in C12Y- Granted patents
- 8
- Published applications
- 25
- Assignees
- 16
- Inventors
- 47
- Latest grant
- 5 Dec 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 2 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 3 |
| 2021 | 0 | 2 |
| 2022 | 0 | 1 |
| 2023 | 2 | 2 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Process for determining enzyme activity in a cell by activity-based reporter gene technology (ABRGT)5 Dec 2023US 11,834,698 B2Indian Institute of Science Education and Research
- Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein14 Mar 2023US 11,603,543 B2Oisin Biotechnologies, Inc.
- Cysteine reactive probes and uses thereof2 Jun 2020US 10,670,605 B2The Scripps Research Institute
- Method for the determination of botulinum neurotoxin biological activity15 Dec 2015US 9,212,355 B2MERZ PHARMA GmbH & CO. KGaA
- Method for the determination of botulinum neurotoxin biological activity4 Aug 2015US 9,096,886 B2MERZ PHARMA GmbH & CO. KGaA
- Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease13 Nov 2025US 2025/0346925 A1Oisin Biotechnologies, Inc.
- Nucleic Acids That Manipulate Immune Pathways16 May 2024US 2024/0158453 A1Children's Medical Center Corporation
- Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein fusogenic lipid nanoparticles and methods of manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease2 Nov 2023US 2023/0348937 A1Oisin Biotechnologies, Inc.
- Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily5 Jan 2023US 2023/0000913 A1King's College London
- Aav cardiac gene therapy for cardiomyopathy in humans25 Aug 2022US 2022/0265858 A1University of Florida Research Foundation, Inc.
Most cited
By later US patents
- Antisense modulation of caspase 8 expression2US 6,258,600 B1Isis Pharmaceuticals, Inc. · 2001
- Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein1US 11,603,543 B2Oisin Biotechnologies, Inc. · 2023
- Function of autophagy genes in cell death1US 7,838,645 B2National Institutes of Health · 2010
- Method for the determination of botulinum neurotoxin biological activity1US 9,096,886 B2MERZ PHARMA GmbH & CO. KGaA · 2015